[San Francisco, CA, December 7, 2023] — Feel Therapeutics, the leading digital precision medicine company that brings objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health, recently announced the results of a study on their platform offered as a digital mental health support program for depression and anxiety in populations with attention-deficit/hyperactivity disorder (ADHD). The study demonstrates the potential impact of continuous passive data monitoring on the outcomes of anxiety and depression in populations with chronic conditions. Specifically, the findings revealed a substantial decrease in depressive and anxiety symptoms (46.2% and 46.4%, respectively) and a notable improvement in life satisfaction (23%). This comes in addition to a previous study published by Feel Therapeutics that demonstrated improvement in outcomes in populations with a primary condition of depression and anxiety.
Recent study validates the effectiveness of their digital precision medicine platform to improve quality of life, life satisfaction, and mental health outcomes in chronic conditions with depression & anxiety comorbidity.
Digital Precision Medicine for mental health provides an innovative solution to the growing global mental health crisis. Mental health is a global crisis. According to the World Health Organization, one out of four individuals will experience a mental disorder, and depression remains one of the leading causes of disability by 2030. While objective measurement tools have been leveraged in almost every medical field for centuries, the field of mental health lags behind, representing a significant shortfall in the effective diagnosis, management, and care of mental health.
Our vision is a world where precision medicine advances the treatment of mental health, enabling proactive and personalized interventions and, ultimately, empowering individuals to live healthier, happier lives,” said George Eleftheriou, CEO and co-founder of Feel Therapeutics.
Feel is leading the way by bringing precision medicine to mental health, starting with the collection of continuous passive and objective data from their proprietary Digital Precision Medicine Platform. Through this platform, Feel translates complex and heterogeneous data to generate a 360-degree view of a patient's mental health. This information serves as a foundation for real-time, personalized support and interventions 24/7/365.
"Our vision is a world where precision medicine advances the treatment of mental health, enabling proactive and personalized interventions and, ultimately, empowering individuals to live healthier, happier lives,” said George Eleftheriou, CEO and co-founder of Feel Therapeutics. “The momentum in this field is undeniable, and by leveraging digital and physiological data from wearables and our mobile phones, we have an incredible opportunity to support individuals in the real world in a personalized way. Whether digital or pharmaceutical interventions, the goal is delivering the right treatment to the right patient at the right time, transforming the management and outcomes in mental health.”
Feel Therapeutics, building on the success of their previous study, has demonstrated that their Digital Precision Medicine Platform not only improves outcomes in depression and anxiety (MDD/GAD) but also extends its benefits to address chronic conditions. A recently released feasibility and usability study reaffirms the platform's value for adults exhibiting ADHD symptomatology while dealing with coexisting depressive or anxiety symptoms – a common use case for the Feel platform.
“Mental and behavioral health is long overdue for its precision medicine revolution,” said Haris Tsirmpas, Co-Founder and CTO of Feel Therapeutics. “In the past, the field leaned heavily on self-reported questionnaires due to a lack of objective measurements. Now, with data collected from wearable devices and mobile sensors, but also voice, video, text, and passive behavioral data, we can extract digital phenotypes and insights. This data paves the way for personalizing treatments, bringing the field closer to the vision of precision medicine. Our goal remains clear: to provide everyone with access to the right diagnoses and care based on reliable, objective data.”
Feel has partnerships with four of the largest pharma and life science companies to generate evidence in clinical and real-world studies, as well as to improve adherence and patient outcomes alongside medications.
To learn more, please visit: www.feeltherapeutics.com
About Feel Therapeutics:
Feel Therapeutics is a Digital Precision Medicine company bringing objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health.
The company is backed by top-tier investors and partners with Pharmaceutical companies and CROs to generate evidence and bring precision Drug+ and DTx solutions to market as standalone or alongside medications.
Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe.